MMX™ mesalamine

Reviews in Gastroenterological Disorders

Volumn 6, Issue 3, 2006, Pages 146-152

  Baker, Daniel E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Crohn's disease; MMX mesalamine; Ulcerative colitis

Indexed keywords

AZULFIDINE EN TABS; BALSALAZIDE; ENEMA; MESALAZINE; MESAVANCE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SPD 476; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; CROHN DISEASE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDUSTRY; DRUG RELEASE; GASTROINTESTINAL DISEASE; HUMAN; HYDROPHILICITY; REVIEW; TABLET; ULCERATIVE COLITIS; DELAYED RELEASE FORMULATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; HUMANS; MESALAMINE;

EID: 33748925941     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Marshall JK, Irvine EJ. Puffing rectal 5-amino-salicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000;95: 1628-1636.
2. Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis. 2005;37:381-388.
3. Bruce LD, Shah NH, Malick AW, et al. Properties of hot-melt extruded tablet formulations for the colonic delivery of 5-aminosalicylic acid. Eur J Pharm Biopharm. 2005:59:85-97.
4. Zou M, Okamoto H, Cheng G, et al. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems. Eur J Pharm Biopharm. 2005;59:155-160.
5. Mahkam M, Doostie L. The relation between swelling properties and cross-linking of hydrogels designed far colon-specific drug delivery. Drug Delivery. 2005;12:343-347.
6. Brunner M, Lackner E, Exler PS, et al. 5-amino-salicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Aliment Pharmacol Ther. 2006;23:137-144.
7. Wilson PJ, Basit AW. Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets. Inter J Pharmaceutics. 2005;300:89-94.
8. 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17:1163-1169.
9. Brunner M, Assandri R, Kletter K, et. al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003;17:395-402.
10. Hanauer SB, Miles S. Therapy of ulcerative colitis. Curr Opin Gastroenterol 2004;20:345-50.
11. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis. 2005;11:421-427.
12. Rochester J, Abreu MT. Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord. 2005;5:215-222.
13. Baker DE. Therapeutic equivalence of mesalamine products. Rev Gastroenterol Disord. 2004;4:25-28.
14. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
15. D'Haens G, Hommes D, Engels L, et al. Once-daily mesalazine with a novel delivery system: a dose-ranging study in patients with acute, mild-to-moderate ulcerative colitis (abstract). Can J Gastroenterol. 2005;19:R.0460.
16. D'Haens G, Hommes D, Engels L, et al. A dose-ranging study of once-daily mesalazine with a novel delivery system in patients with acute, mild-to-moderate ulcerative colitis (abstract). Gut. 2005;54:A56.
17. Baxter ES, Baccari M. Mesavance™ (SPD476) phase III ulcerative colitis study results presented at the 70th Annual American College of Gastroenterology (ACG). Press Release. Shire Pharmaceutical. November 1 2005.
18. PRNewswire. SPD476 Phase II and Phase III study results presented at the 13th Annual United European Gastroenterology Week (UEGW). PRNewswire.com October 19 2005. Available at: www.prnewswire.co.uk/cgi/news/ release?id-156326. Accessed January 26, 2006.
19. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. SPD476 is a novel, once-daily, high-dose, effective and well tolerated 5-ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study (abstract). Am J Gastroenterol. 2005;100:S291-S292:787
20. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. SPD476, a novel, once-daily, high-dose, mesalamine formulation is well tolerated and affective for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study (abstract). Gut. 2005;54:A82.
21. Lichtenstein G, Kamm M, Sandborn W, et al. Mesavance™ (SPD476), a novel, once-daily, high-dose 5-ASA formulation is effective and well tolerated for the induction of remission of mild-to-moderate colitis: a phase III study (SPD476-30l) (abstract). Can J Gastroenterol. 2006;20:145.
22. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. Once vs twice daily dosing of SPD476, a novel 5-ASA formulation for remission of mild-to-moderate ulcerative colitis. (abstract) Crohn's & Colitis Foundation of America National Research and Clinical Conference. 4th Annual Advances in the Inflammatory Bowel Disease (AIBD). Miami Beach, FL; December 1-3 2005.
23. Kamm MA, Sandborn WJ, Gassull M, et al. Comparison of the efficacy and safety of SPD476, a novel, once-daily, high-dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study (abstract). Am J Gastroenterol. 2005;100:S291:786
24. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily SPD476, a novel, high-dose formulation of 5-ASA induces remission in mild-to-moderate UC. Crohn's & Colitis Foundation of America National Research and Clinical Conference. 4th Annual Advances in the Inflammatory Bowel Disease (AIBD). Miami Beach, FL; December 1-3, 2005.
25. Kamm MA, Sandborn W, Gassull M, et al. Once-daily Mesavance™ (SPD476], a novel, high-strength formulation of mesalamine, induces remission of mild-to-moderate ulcerative colitis, while ASACOL® does not: a phase III study (SPD476-302) (abstract). Can J Gastroenterol. 2006;20:146.
26. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III studies (abstract). Digestive Disease Week 2006. Los Angeles, CA; May 20-25, 2006; T1148.
27. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. Once- and twice-daily SPD476, a novel, high-strength formulation of 5-ASA, induces remission of both mild and moderate ulcerative colitis: a prespecified analysis of combined data from two pivotal, randomized, placebo-controlled, phase III studies (abstract). Digestive Disease Week 2006. Los Angeles, CA; May 20-25, 2006; T1147.
28. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. Combined data from two pivotal, randomized, placebo-controlled, phase III studies show that SPD476, a novel mesalamine formulation given once or twice-daily, is effective for the induction of remission of mild-to-moderate ulcerative colitis (abstract). Digestive Disease Week 2006; Los Angeles, CA; May 20-25, 2006; 813.
29. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. SPD476, a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naïve: an analysis of pooled data from two phase III studies (abstract). Digestive Disease Week 2006. Los Angeles, CA; May 20-25, 2006;T1139.
30. Efficacy and safety of SPD476 in maintaining remission in patients with ulcerative colitis. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/NCT00151892. Accessed January 26, 2006.
31. Safety and tolerability of SPD476 in maintaining remission in patients with ulcerative colitis. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/NCT00151944. Accessed January 26, 2006.
32. Shire Press Release: Shire announces filing of Mesavance™ (mesalamine) for treatment of ulcerative colitis. Singapore: Shire Pharmaceuticals; December 22, 2005. Available at: www.shire.com. Accessed March 31, 2006.